LX-1031 is an oral drug candidate for IBS and other gastrointestinal disorders. LX-1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels. LX-1031 is designed to act locally in the gastrointestinal (GI) tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system functions.

The target of LX-1031 is tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin. Lexicon discovered that mice lacking TPH1, the form of this enzyme found predominantly in the gastrointestinal tract, have virtually no peripheral serotonin but normal levels of brain serotonin.

Highest Dev Status	Phase 2
Therapeutic Area	Gastrointestinal
Potential Indications	Please Login
Identified Action Mechanisms	1
Literature	NCBI